The Blood Glucose Level Increased in Parallel with the Heart Rate Following Cilostazol Administration in Three Diabetic Patients

Aoki, Yuji; Shimizu, Mika; Watanabe, Nobuaki

doi:10.2169/internalmedicine.53.1403

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serious adverse reactions include atrial fibrillation, cardiac arrest, myocardial infarction, and ventricular tachycardia, as well as bleeding and hemorrha-ging [27]. In a case report including three patients, a potential relationship between cilostazol-induced tachycardia and hyperglycemia was observed [28]. All three patients had a past medical history of type 2 diabetes and were admitted for cerebral infarction.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Effect of cilostazol in treating diabetes-associated microvascular complications

Asal

Wojciak

2017

Endocrine

View full text Add to dashboard Cite

Purpose Cilostazol (Pletal), a phosphodiesterase-3 inhi-bitor, was approved in the United States in 1999 to reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition of phos-phodiesterase resulting in anti-platelet, anti-inflammatory, and vasodilatory effects. Diabetes mellitus is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and macrovascular compli-cations. This mini-review highlights the emerging evidence suggesting benefits of using cilostazol in treating micro-vascular complications associated with diabetes mellitus. Methods A review of literature was conducted using PubMed and Embase databases focusing on cilostazol use in diabetes mellitus. Results Cilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum soluble adhesion molecule-1 and monocyte chemoattractant protein-1. Cilostazol's anti-inflammatory actions predictably attenuate glomerular damage from increased leukocyte adherence. Additionally, cilostazol delayed renal dysfunc-tion secondary to type 2 diabetes mellitus as albuminuria was reduced most likely resulting from inhibition of nuclear factor kappa-induced inflammatory and endothelial mar-kers. Cilostazol's antiinflammatory actions in addition to its vasodilatory actions relieved retinal hypoxia and decreased excessive production of retinal blood vessels suggesting benefit in diabetic retinopathy. Cilostazol did not improve

show abstract

Section: Adverse Reactionsmentioning

confidence: 99%

Effect of cilostazol in treating diabetes-associated microvascular complications

Asal

Wojciak

2017

Endocrine

View full text Add to dashboard Cite

show abstract

“…There exists concern that PTX might exert a negative impact on glycemic control in patients with diabetes. Previous studies have shown that PDE3,4 inhibitors enhance both glycogenolysis and gluconeogenesis in hepatocytes isolated from fasted rats [ 97 ], and the blood glucose level increases following the administration of cilostazol, a PDE3 inhibitor, in three patients with type 2 diabetes [ 98 ]. More recently, however, PDE4 inhibitors have been shown to improve glucose homeostasis in diabetic mice [ 99 ] and human patients [ 100 ], likely via enhancing the secretion of cAMP-mediated glucagon-like peptide 1 [ 99 ].…”

Section: Main Textmentioning

confidence: 99%

Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update

et al. 2017

View full text Add to dashboard Cite

Blood pressure control with renin-angiotensin system (RAS) blockade has remained the gold standard for treating patients with proteinuric chronic kidney disease (CKD) up to date. Nevertheless, RAS blockade slows but does not halt the progression of kidney disease, thus highlighting the need to search for additional therapeutic approaches. The nonselective phosphodiesterase (PDE) inhibitor pentoxifylline (PTX) is an old drug that exhibits prominent anti-inflammatory, anti-proliferative and anti-fibrotic activities both in vitro and in vivo. Studies in human subjects have shown that PTX monotherapy decreases urinary protein excretion, and add-on therapy of PTX to background RAS blockade additively reduces proteinuria in patients with CKD of various etiology. More recent studies find that PTX combined with RAS blockade delays the decline of glomerular filtration rate in diabetic patients with mild to moderate CKD, and reduces the risk of end-stage renal disease in diabetic and non-diabetic patients in late stage of CKD with high proteinuria levels. In this review, we update the clinical trial results of PTX as monotherapy, or in conjunction or in comparison with RAS blockade on patients with proteinuria and CKD, and propose a mechanistic scheme explaining the renoprotective activities of this drug.

show abstract

Cilostazol

2014

Reactions Weekly

View full text Add to dashboard Cite

The Blood Glucose Level Increased in Parallel with the Heart Rate Following Cilostazol Administration in Three Diabetic Patients

Cited by 5 publications

References 20 publications

Effect of cilostazol in treating diabetes-associated microvascular complications

Effect of cilostazol in treating diabetes-associated microvascular complications

Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update

Cilostazol

Contact Info

Product

Resources

About